Published in J Exp Med on November 01, 1968
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Proteins spcified by herpes simplex virus. II. Viral glycoprotins associated with cellular membranes. J Virol (1970) 4.20
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection. J Virol (1979) 2.90
Immunity to malignant disease in man. Br Med J (1969) 2.88
Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis. J Virol (1981) 2.74
Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. J Virol (1979) 1.71
Two-colour immunofluorescence studies on EBV-determined antigens. Clin Exp Immunol (1971) 1.60
Human lymphoblastoid cell lines and Epstein-Barr virus: a review of their interrelationships and their relevance to the etiology of leukoproliferative states in man. Yale J Biol Med (1971) 1.38
Antibodies against membrane antigens of cytomegalovirus infected cells in sera of patients with a cytomegalovirus infection. Clin Exp Immunol (1972) 1.34
Antibodies to surface antigens of herpesvirus type 1- and type 2-infected cells among women with cervical cancer and control women. Infect Immun (1972) 1.30
Relation between Epstein-Barr viral and cell membrane immunofluorescence in Burkitt tumor cells. IV. Differentiation between antibodies responsible for membrane and viral immunofluorescence. J Exp Med (1969) 1.26
The interaction of normal lymphocytes and cells from lymphoid cell lines. I. The nature of the activation process. Immunology (1970) 1.22
Inhibition of herpes virus-induced cell fusion by concanavalin A, antisera, and 2-deoxy-D-glucose. J Virol (1974) 1.14
Detection of antibody to respiratory syncytial virus by membrane fluorescence. Clin Exp Immunol (1976) 1.06
Immunological studies on Burkitt's lymphoma. Postgrad Med J (1971) 1.04
Radioimmunoassay for detection of antibodies to Epstein-Barr virus in human infectious mononucleosis serum specimens. J Clin Microbiol (1975) 1.03
Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol (1990) 0.95
Separation of spontaneous-killing effector populations by target preference. Br J Cancer (1980) 0.94
Complement-fixation test for detection of herpes-like viruses in cell cultures of Burkitt's lymphoma. J Virol (1969) 0.93
Papain solubilization of the Epstein-Barr virus-induced membrane antigen. J Virol (1978) 0.93
Anti-class II antibodies in AIDS patients and AIDS-risk groups. Immunology (1987) 0.93
Rapid subtyping of influenza A virus isolates by membrane fluorescence. J Clin Microbiol (1979) 0.90
Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus. Clin Exp Immunol (1982) 0.87
Cell surface antigen induced by venezuelan equine encephalomyelitis virus. Infect Immun (1970) 0.85
Effects of activated T cells on natural killing. Immunology (1982) 0.84
Solubilization and characterization of Herpesvirus saimiri-induced membrane antigens. J Virol (1978) 0.84
Reactivity of radioiodinated serum antibody from Burkitt's lymphoma and nasopharyngeal carcinoma patients against culture lines derived from Bukrkitt's lymphoma. Clin Exp Immunol (1970) 0.81
Complement-fixing antigens in Burkitt lymphoma cell lines. Infect Immun (1971) 0.78
Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule. Cancer Sci (2014) 0.78
Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined antigens. III. Reactivity in sera from patients with Burkitt's lymphoma in relation to tumour development. Clin Exp Immunol (1977) 0.77
Isolation of virus-free Herpesvirus saimiri antigen-positive plasma membrane vesicles. Proc Natl Acad Sci U S A (1977) 0.76
Surface antigens on lymphoblastoid cells derived from nasopharyngeal carcinoma. Clin Exp Immunol (1970) 0.76
Antibody responses to herpesviruses (EBV, HSV and CMV) in cancer patients given cultured lymphoblastoid cells. Clin Exp Immunol (1972) 0.75
Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol (1966) 18.33
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol (1967) 8.29
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
BURKITT TUMOR: TISSUE CULTURE, CYTOGENETIC AND VIRUS STUDIES. J Natl Cancer Inst (1965) 6.90
Culture of normal human leukocytes. JAMA (1967) 4.50
Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. JAMA (1968) 4.26
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells. J Bacteriol (1966) 2.42
Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy. J Virol (1967) 2.07
Continuous culture of seven new cell lines (SK-L1 to 7) from patients with acute leukemia. Cancer (1967) 1.75
AMINO ACID REQUIREMENTS OF HERPES SIMPLEX VIRUS IN HUMAN CELLS. J Bacteriol (1964) 1.65
Studies on cell lines derived from Burkitt's lymphoma. Trans N Y Acad Sci (1966) 1.60
Specific immunofluorescence test for the herpes-type EB virus of Burkitt lymphoblasts, authenticated by electron microscopy. J Natl Cancer Inst (1968) 1.54
The role of arginine in the replication of herpes simplex virus. J Gen Virol (1967) 1.46
Serial cultivation of human leukemic cells. Proc Soc Exp Biol Med (1966) 1.35
Effect of arginine-deficient media on the herpes-type virus associated with cultured Burkitt tumor cells. J Virol (1968) 1.33
The coating reaction of the herpes-type virus isolated from malignant tissues with an antibody present in sera. Cancer Res (1967) 1.29
[Nutritional factors influencing the growth of herpes virus in Earle's strain of L cells]. Ann Inst Pasteur (Paris) (1959) 1.05
Studies of Burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics. Cancer (1967) 0.97
Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol (1966) 18.33
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
Small-area variations in the use of common surgical procedures: an international comparison of New England, England, and Norway. N Engl J Med (1982) 12.33
INTERFERENCE OF INACTIVE VIRUS WITH THE PROPAGATION OF VIRUS OF INFLUENZA. Science (1943) 10.31
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (2006) 7.88
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science (1970) 7.60
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
THE DEMONSTRATION OF ONE-STEP GROWTH CURVES OF INFLUENZA VIRUSES THROUGH THE BLOCKING EFFECT OF IRRADIATED VIRUS ON FURTHER INFECTION. J Exp Med (1947) 5.91
The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 5.58
Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care. Intensive Care Med (1997) 5.36
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
MAP kinases. Chem Rev (2001) 4.70
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
STUDIES ON THE NATURE OF THE VIRUS OF INFLUENZA : I. THE DISPERSION OF THE VIRUS OF INFLUENZA A IN TISSUE EMULSIONS AND IN EXTRA-EMBRYONIC FLUIDS OF THE CHICK. J Exp Med (1943) 4.30
A microassay for cell-mediated immunity. Transplantation (1970) 4.29
Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. JAMA (1968) 4.26
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell (1983) 4.22
Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst (1966) 4.19
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol (1999) 3.96
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature (1978) 3.73
NEUROLOGICAL SIGNS IN MICE FOLLOWING INTRACEREBRAL INOCULATION OF INFLUENZA VIRUSES. Science (1944) 3.61
Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol (1974) 3.58
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1966) 3.56
Suppression of malignancy by cell fusion. Nature (1969) 3.41
Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer (1976) 3.36
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst (1971) 3.30
Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cell Immunol (1973) 3.17
THE EFFECT OF VITAMIN B(1) DEFICIENCY AND OF RESTRICTED FOOD INTAKE ON THE RESPONSE OF MICE TO THE LANSING STRAIN OF POLIOMYELITIS VIRUS. J Exp Med (1944) 3.17
SEROLOGICAL SPECIFICITY OF HEAVY PARTICLES DERIVED FROM NORMAL ORGANS. Science (1940) 3.12
Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Epidemiology of cytomegalovirus infection after transplantation and immunosuppression. J Infect Dis (1975) 3.02
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer (1971) 3.00
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer (1972) 2.80
Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells. J Bacteriol (1966) 2.79
Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. Philos Trans R Soc Lond B Biol Sci (1994) 2.76
Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res (1982) 2.68
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Further studies on the treatment of Burkitt's lymphoma. East Afr Med J (1966) 2.61
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
EB virus-induced B lymphocyte cell lines producing specific antibody. Nature (1977) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
STUDIES ON THE COMPLEMENT FIXATION ANTIGENS OF INFLUENZA VIRUSES TYPES A AND B. J Exp Med (1946) 2.50